COMMUNIQUÉS West-GlobeNewswire

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
16/07/2026
First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both [...]
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
16/07/2026
BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report [...]
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
16/07/2026
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Former Smith+Nephew Global Orthopaedics President Craig Gaffin Joins MedEdge Holdings as Partner
16/07/2026
Healthcare industry veteran brings more than 25 years of commercial leadership experience to help expand MedEdge's platform for acquiring, building and commercializing innovative surgical technology companies GREENWICH [...]
Rinascera Therapeutics Launches with Clinical-Stage Pipeline to Transform the Treatment of Genetic Skin Diseases
16/07/2026
- Initial financing led by Double Point Ventures with participation from Olive Tree Capital, Civilization Ventures and Toba Capital - - Supports advancement of RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic [...]
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry’s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed/Refractory B Cell Malignancies
16/07/2026
The company’s lead internal program expands its in vivo CAR T clinical pipeline for patients with relapsed/refractory B cell malignancies First patient expected to be dosed in Q3 2026 SEATTLE, July 16, 2026 (GLOBE [...]
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
16/07/2026
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, July 16, 2026 ( [...]
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
16/07/2026
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for Alcohol Use [...]
Better Blend to open two new Cincinnati-area locations
16/07/2026
New Hyde Park and Kenwood locations strengthen Greater Cincinnati presence CINCINNATI, July 16, 2026 (GLOBE NEWSWIRE) -- Better Blend, the Northern Kentucky-founded smoothie and wellness brand, is continuing its rapid [...]
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
16/07/2026
Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancer BriaCell Phase 3 trial featured in Nature Medicine [...]
Sonus Microsystems’ Autonomous Ultrasound AI Platform Selected for Major ARPA-H Maternal Health Award
16/07/2026
Sonus’s ultrasound AI platform will power a point-of-care test that enables frontline clinicians to better assess placental health and flag pregnancies at risk of fetal hypoxia. VANCOUVER, British Columbia, July 16, [...]
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
16/07/2026
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells [...]
SRX Global Regains Full Compliance with NYSE American Listing Standards
16/07/2026
Company Resolves Section 1003(a)(i) and (ii) Deficiencies; Compliance Indicator to Be Removed NORTH PALM BEACH, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the "Company", or "SRX"), an [...]
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
16/07/2026
Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the [...]
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
16/07/2026
First-in-class clustering agonist antibody DIAG723 is designed to restore ALK1 signaling, the genetically disrupted pathway that causes abnormal vascular development, bleeding, and arteriovenous malformations (AVMs) in [...]
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
16/07/2026
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
16/07/2026
Sales Highlights (unaudited): Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp) 2H FY26 sales AUD$3.5 million up 7% on pcp 4Q FY26 sales AUD$2.0 million up 2% on pcp Australia FY26 sales AUD$5.8 [...]
BienRaíz Launches 240 mg Magnesium Glycinate Supplement, Expanding Its Daily Wellness Portfolio with Targeted Mineral Support
16/07/2026
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- BienRaíz today announced the launch of BienRaíz Magnesium Glycinate Supplement, a daily magnesium glycinate supplement formulated with 240 mg elemental magnesium per serving. [...]
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
16/07/2026
www.arlettapharmasolutions.com FDA endorses key elements of the proposed Phase 2 dose-ranging study and openness to a single pivotal Phase 3 study to support a future NDA Amsterdam, the Netherlands, 16 July 2026 — [...]

Pages